Genmab and GlaxoSmithKline initiated a Phase III program with ofatumumab to treat rheumatoid arthritis (RA). The program will begin with two studies (GEN410/OFA110635 and GEN411/OFA110634) in two patient populations. One study will include patients who have had an inadequate response to methotrexate therapy and the other in patients who had an inadequate response to TNF-alpha antagonist therapy. Additional studies are planned for 2008. The studies will evaluate the efficacy of ofatumumab in...